Cefepime-zidebactam (FEP-ZID) is a novel β-lactam/β-lactam enhancer combination that offers a mechanistically distinct approach to overcoming resistance in Gram-negative organisms. FREE TO READ: buff.ly/zk8Xbus
Latest posts 5
Literature suggests that incretin mimetics offer an opportunity for a shift in how medicine approaches AUD, leveraging multifaceted pathology to reduce alcohol consumption, craving intensity, health care utilization, and alcohol-related complications. buff.ly/kNMS3Fn
NSAIDs were not associated with an increased risk of clinically significant progression of intracranial bleed in patients with acute TBI when administered within 14 days of injury. NSAIDs appear safe in the acute phase post-TBI. OPEN ACCESS: buff.ly/jsTg18u
Although valuable for hypothesis generation and literature retrieval, LLM outputs should not be used in isolation for drug dosing in critically ill patients with kidney dysfunction. buff.ly/7L8P5nS
Model predictiveness of vancomycin concentrations was worse in patients with AKI, especially in pediatrics and neonates, and generally less pronounced in persistent versus new-onset AKI. OPEN ACCESS: buff.ly/ZzwTvX7
